Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 178(7): 1588-1604, 2021 04.
Article in English | MEDLINE | ID: mdl-33491188

ABSTRACT

BACKGROUND AND PURPOSE: Src homology 3-domain growth factor receptor-bound 2-like endophilin interacting protein 1 (SGIP1) interacts with cannabinoid CB1 receptors. SGIP1 is abundantly and principally expressed within the nervous system. SGIP1 and CB1 receptors co-localize in axons and presynaptic boutons. SGIP1 interferes with the internalization of activated CB1 receptors in transfected heterologous cells. Consequently, the transient association of CB1 receptors with ß-arrestin2 is enhanced and prolonged, and CB1 receptor-mediated ERK1/2 signalling is decreased. Because of these actions, SGIP1 may modulate affect, anxiety, pain processing, and other physiological processes controlled by the endocannabinoid system (ECS). EXPERIMENTAL APPROACH: Using a battery of behavioural tests, we investigated the consequences of SGIP1 deletion in tasks regulated by the ECS in SGIP1 constitutive knockout (SGIP1-/- ) mice. KEY RESULTS: In SGIP1-/- mice, sensorimotor gating, exploratory levels, and working memory are unaltered. SGIP1-/- mice have decreased anxiety-like behaviours. Fear extinction to tone is facilitated in SGIP1-/- females. Several cannabinoid tetrad behaviours are altered in the absence of SGIP1. SGIP1-/- males exhibit abnormal behaviours on Δ9 -tetrahydrocannabinol withdrawal. SGIP1 deletion also reduces acute nociception, and SGIP1-/- mice are more sensitive to analgesics. CONCLUSION AND IMPLICATIONS: SGIP1 was detected as a novel protein associated with CB1 receptors, and profoundly modified CB1 receptor signalling. Genetic deletion of SGIP1 particularly affected behavioural tests of mood-related assessment and the cannabinoid tetrad. SGIP1-/- mice exhibit decreased nociception and augmented responses to CB1 receptor agonists and morphine. These in vivo findings suggest that SGIP1 is a novel modulator of CB1 receptor-mediated behaviour.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Nociception , Receptor, Cannabinoid, CB1 , Affect , Animals , Cannabinoids , Emotions , Extinction, Psychological , Fear , Female , Male , Mice , Mice, Knockout , Receptor, Cannabinoid, CB1/genetics , Receptors, Cannabinoid
2.
Neuropharmacology ; 107: 201-214, 2016 08.
Article in English | MEDLINE | ID: mdl-26970018

ABSTRACT

Many diseases of the nervous system are accompanied by alterations in synaptic functions. Synaptic plasticity mediated by the endogenous cannabinoid system involves the activation of the cannabinoid receptor 1 (CB1R). The principles of CB1R signaling must be understood in detail for its therapeutic exploration. We detected the Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1 (SGIP1) as a novel CB1R partner. SGIP1 is functionally linked to clathrin-mediated endocytosis and its overexpression in animals leads to an energy regulation imbalance resulting in obesity. We report that SGIP1 prevents the endocytosis of activated CB1R and that it alters signaling via the CB1R in a biased manner. CB1R mediated G-protein activation is selectively influenced by SGIP1, ß-arrestin associated signaling is changed profoundly, most likely as a consequence of the prevention of the receptor's internalization elicited by SGIP1.


Subject(s)
Carrier Proteins/metabolism , Endocytosis/physiology , Receptor, Cannabinoid, CB1/metabolism , Adaptor Proteins, Signal Transducing , Animals , Brain/metabolism , Carrier Proteins/genetics , Cell Membrane/drug effects , Cell Membrane/metabolism , Endocytosis/drug effects , HEK293 Cells , Humans , MAP Kinase Signaling System/physiology , Mice , Neurons/metabolism , Rats, Wistar , Saccharomyces cerevisiae , Transfection , Two-Hybrid System Techniques , beta-Arrestin 2/metabolism
3.
Neuropharmacology ; 86: 329-336, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25158311

ABSTRACT

The assembly of two covalently linked monomers into dimeric complexes is a prerequisite for metabotropic glutamate receptor 1 (mGluR1) function. The former concept of a strictly homodimeric subunit contribution in metabotropic glutamate receptor complexes has recently been brought into question. Alternative splicing of the GRM1 gene results in expression of variants that vary within their intracellular C-termini. Here we bring evidence that the short mGluR1b variant is found preferentially in a complex with the long mGluR1a variant in the rodent brain. The mGluR1a and mGluR1b variants distribution overlaps in Purkinje cells and the two variants colocalize in their spines. However mGluR1a and mGluR1b show distinct sub-cellular localization when expressed alone in neurons. We discovered that trafficking of mGluR1b to distal dendrites is reliant on its association with mGluR1a and that the long C-terminus of mGluR1a within the mGluR1a/b dimer is necessary for trafficking of the complex.


Subject(s)
Brain/metabolism , Neurons/metabolism , Receptors, Metabotropic Glutamate/metabolism , Animals , Biological Transport, Active , Cells, Cultured , Dendritic Spines/metabolism , Dimerization , Electrophoresis, Polyacrylamide Gel , HEK293 Cells , Humans , Immunoblotting , Immunohistochemistry , Male , Microscopy, Electron , Protein Isoforms , Rats , Rats, Sprague-Dawley , Rats, Wistar , Subcellular Fractions/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...